Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder

Journal of Investigative Dermatology

Volumn 132, Issue 6, 2012, Pages 1627-1635

  Leslie Pedrioli, Deena M ^a   Fu, Dun Jack ^a   Gonzalez Gonzalez, Emilio ^b   Contag, Christopher H ^b   Kaspar, Roger L ^b,c   Smith, Frances J D ^a   McLean, W H Irwin ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TransDerm   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 9; GENERIC DRUG; LUCIFERASE; PROTEIN ANTIBODY; SIKRT9 1; SIKRT9 2; SIKRT9 3; SIKRT9 4; SIKRT9 5; SIKRT9 6; SIR163Q 13; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; EPIDERMOLYTIC PALMOPLANTAR KERATODERMA; GENE MUTATION; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MOUSE; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REPORTER GENE; RNA INTERFERENCE;

EID: 84861184577     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.28     Document Type: Article

References (26)

1. Atkinson SD, McGilligan VE, Liao H et al. (2011) Development of allelespecific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J Invest Dermatol 131:2079-86
2. Coulombe PA, Tong X, Mazzalupo S et al. (2004) Great promises yet to be fulfilled: defining keratin intermediate filament function in vivo. Eur J Cell Biol 83:735-46 (Pubitemid 40123838)
3. Covello SP, Irvine AD, McKenna KE et al. (1998) Mutations in keratin K9 in kindreds with epidermolytic palmoplantar keratoderma and epidemiology in Northern Ireland. J Invest Dermatol 111:1207-9 (Pubitemid 29115200)
4. Davidson BL, McCray PB Jr (2011) Current prospects for RNA interferencebased therapies. Nat Rev Genet 12:329-40
5. Fire A, Xu S, Montgomery MK et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-11 (Pubitemid 28099681)
6. Fogarty GB, Conus NM, Chu J et al. (2007) Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 156:92-8 (Pubitemid 44924151)
7. Gonzalez-Gonzalez E, Ra H, Spitler R et al. (2010) Increased interstitial pressure improves nucleic acid delivery to skin enabling a comparative analysis of constitutive promoters. Gene Ther 17:1270-8
8. Hickerson RP, Smith FJ, Reeves RE et al. (2008) Single-nucleotide- specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 128:594-605 (Pubitemid 351252662)
9. Ketting RF (2011) The many faces of RNAi. Dev Cell 20:148-61
10. Lane EB, McLean WHI (2008) Broken bricks and cracked mortar - epidermal diseases resulting from genetic abnormalities. Drug Discov Today Dis Mech 5:393-401
11. Langbein L, Heid HW, Moll I et al. (1993) Molecular characterization of the body site-specific human epidermal cytokeratin 9: cDNA cloning, amino acid sequence, and tissue specificity of gene expression. Differentiation 55:57-71 (Pubitemid 24006223)
12. Leachman SA, Hickerson RP, Schwartz ME et al. (2010) First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 18:442-6
13. Liao H, Irvine AD, MacEwen CJ et al. (2011) Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy. PLoS One 6:e28582
14. Lu H, Zimek A, Chen J et al. (2006) Keratin 5 knockout mice reveal plasticity of keratin expression in the corneal epithelium. Eur J Cell Biol 85: 803-11 (Pubitemid 44087887)
15. Magin TM, Schroder R, Leitgeb S et al. (1998) Lessons from keratin 18 knockout mice: formation of novel keratin filaments, secondary loss of keratin 7 and accumulation of liver-specific keratin 8-positive aggregates. J Cell Biol 140:1441-51 (Pubitemid 28152992)
16. McLean WH, Irvine AD (2007) Disorders of keratinisation: from rare to common genetic diseases of skin and other epithelial tissues. Ulster Med J 76:72-82 (Pubitemid 46566890)
17. McLean WHI, Moore CBT (2011) Keratin disorders - from gene to therapy. Hum Mol Genet 20(R2):R189-97
18. Napoli C, Lemieux C, Jorgensen R (1990) Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2:279-89 (Pubitemid 120029588)
19. Omary MB, Coulombe PA, McLean WHI (2004) Intermediate filament proteins and their associated diseases. New Engl J Med 351: 2087-2100 (Pubitemid 39482502)
20. Porter RM, Lane EB (2003) Phenotypes, genotypes and their contribution to understanding keratin function. Trends Genet 19:278-85 (Pubitemid 36507010)
21. Reis A, Hennies HC, Langbein L et al. (1994) Keratin 9 gene mutations in epidermolytic palmoplantar keratoderma (EPPK). Nat Genet 6:174-9 (Pubitemid 24188599)
22. Smith F (2003) The molecular genetics of keratin disorders. Am J Clin Dermatol 4:347-64 (Pubitemid 36560720)
23. Smith FJ, Hickerson RP, Sayers JM et al. (2008) Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol 128: 50-8 (Pubitemid 350249391)
24. Swensson O, Langbein L, McMillan JR et al. (1998) Specialized keratin expression pattern in human ridged skin as an adaptation to high physical stress. Br J Dermatol 139:767-75 (Pubitemid 28520281)
25. Szeverenyi I, Cassidy AJ, Chung CW et al. (2008) The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat 29:351-60 (Pubitemid 351364936)
26. Wong P, Domergue R, Coulombe PA (2005) Overcoming functional redundancy to elicit pachyonychia congenita-like nail lesions in transgenic mice. Mol Cell Biol 25:197-205 (Pubitemid 40039811)